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Metastatic breast cancer is a disease of early breast cancer that usually occurs several
years after the early breast cancer. Breast cancer is the most common cancer among
Iranian women. According to the new statistics in Iran 6160 breast cancers are diagnosed
in the country each year and 1063 cases lead to death. In this paper, epidemiology,
diagnosis and treatment have been investigated. In this study, case–control clinical trials
and open studies with adequate data were collected. Due to the higher risk of age group
40–49 years and the advent of advanced breast cancer in Iranian women, the early
diagnosis and determination of the exact size of the tumor before surgery is important in
choosing a therapy plan. The decision on the therapy of invasive breast cancer depends on
several factors such as cancer stage, tumor size and type, pathological and cytological
status of the tumor, the patient's opinion, the presence or absence of estrogen and pro-
gesterone receptors in the cytoplasm of tumor cells and so on.1. Introduction
Metastatic breast cancer is a disease of early breast cancer
that usually occurs several years after the early breast cancer [1].
Breast cancer is the most common cancer among Iranian women
(24.4% of all cancers) and its crude incidence is 17.8%
according to the statistics of 2005–2006 [2–4]. According to
the studies conducted in 2005–2006, the incidence of breast
cancer in Iranian women was 13.3% and 10% of all breast
cancer cases in Iran observed in Isfahan [5]. According to the
report of World Health Organization, the incidence of breast
cancer has annually increased by 2% [6]. According to the new
statistics in Iran, 6160 breast cancers are diagnosed in the
country each year and 1063 cases lead to death [7,8]. Although
the incidence of breast cancer in Asian women is low
compared to women in western countries, its incidence trend
is considered higher. Breast cancer affects the Iranian women
at least a decade earlier than women in developed countries
and most of the patients with this disease are in the age of40–49 years old in Iran [9]. According to the statistics in 2007,
at the time of diagnosis, 18% of patients were in stage I, 57%
in stage II, 25% in stage III, 72% of patients had tumors
larger than 2 cm and 63% had the involvement of lymph
nodes at diagnosis [7]. The symptoms of benign conditions are
similar to those found in breast cancer and may cause great
concern until evaluated and explained by a qualified health
professional [10,11].
In total, about 6% of breast cancers were metastatic at
diagnosis (5-year survival rate of 21%). The incidence of met-
astatic disease is high because many women with this disease
live for several years [10]. Distant metastasis is the cause of 90%
of deaths from breast cancer [12]. And despite the advances in the
diagnosis and therapy of breast cancer, more than 44 000 women
die of metastatic disease in the United States [13].
Breast cancer primarily metastasize bones, lungs, regional
lymph nodes, the liver and brain [14]. Approximately, 70% of
patients with advanced breast cancer have bone metastasis.
Bone is the most commonly observed site for distant
metastases and is the location of 30%–40% of first tumor
recurrence [15]. The women whose first recurrence occurs in
skeleton have a better prognosis than those with visceral
metastasis to the liver, lungs or brain. Most bone metastases
can be successfully controlled for a long time [16–18]. Brainan open access article under the CC BY-NC-ND
Hamidreza Alizadeh Otaghvar et al./Asian Pac J Trop Biomed 2015; 5(6): 429–433430metastasis has been observed in 10% of breast cancer patients
with metastatic properties [19,20].
Although the objective answers to some chemotherapy reg-
imens are common, but a few number of patients with metastatic
disease are treated and the therapy often has significant side
effects [21]. Nutrition and diet play an important role in breast
cancer and may alter disease progression [22,23]. Several
studies have shown that obese women are at a high risk for
breast cancer metastasis to distant sites [24–26].
Due to the higher risk of age group 40–49 years and the
advent of advanced breast cancer in Iranian women, the early
diagnosis and determination of the exact size of the tumor before
surgery is important in choosing a therapy plan [27].
2. Diagnosis
Breast exam by doctors or by the women herself and getting
mammograms are recommended to all women especially those
over 40 years old for screening and early diagnosis. Sonography,
magnetic resonance imaging and histopathology tests are needed
for diagnosis in the next phases [28,29].
In addition to histopathological diagnosis, molecular and
cellular tumor markers can help the diagnosis. Today, particular
attention is paid to the use of sensitive, quick and cheap tech-
niques, one of which is the use of tumor markers [30,31]. A small
number of tumor markers has been accepted for routine use in
breast cancer [32]. For example, mammaglobin has been
considered a specific diagnostic marker for breast cancer [33].
In assessing human epidermal growth factor receptor 2
(HER2) and chitinase-3-like protein 1, also known as YKL-
40, in patients with early diagnosis of recurrence and breast
cancer metastasis, the serum level of these two tumor markers
has been increased in patients compared to healthy women
[34,35]. In another study, the measurement of angiostatin in the
urine of patients with breast cancer is a non-invasive method
for the diagnosis of cancer [36].
Results show that there is no a specific correlation between the
amounts of serum matrix metallopeptidase 9 and lymphatic
metastasis with venous invasion [37]. Thus, for the early diagnosis
of breast cancer, plasma levels of this enzyme are more
appropriate than its serum levels [38,39]. Cancer antigen 15-3
(CA15-3), carcinoembryonic antigen (CEA) and erythrocyte
sedimentation rate are other valid markers [40]. In the study of
CEA and CA15-3 level of sensitivity in breast tumors with
metastasis to the axillary lymph nodes, tumor marker CA15-3 can
be used to identify the presence or absence of metastasis of
axillary lymph node in breast cancer. However, CEA does not
have an appropriate sensitivity in this context [41,42].
In the study of the correlation between serum and salivary
concentrations of HER2/neu, also called c-erbB2, in women
with breast cancer, it seems that there is little correlation be-
tween serum and salivary concentrations of c-erbB2 in the early
stages of breast cancer and also the absence of metastasis [43,44].
Breast cancer is uncommon in men, but has increased in the
last 25 years. Breast cancer is diagnosed in men in a higher stage
and age. HER2/neu expression is more than women [45,46].
2.1. Diagnostic imaging
According to the studies that have been conducted, sonog-
raphy is a more reliable diagnostic method in diagnosing thelesions in patients with high density mammography (class 3 and
class 4), but mammography is more accurate than sonography in
determining the size of the tumor before surgery. Thus, the so-
nography alone before the surgery is not a suitable means for
diagnosing the lymph node metastasis [47,48].
A variety of imaging techniques such as computerized to-
mography scan, magnetic resonance imaging or positron emis-
sion tomography scan can be used for detection of bone
metastasis. But none of them is suitable for the diagnosis and
evaluation of response to therapy. The use of positron emission
tomography scan for evaluating breast cancer recurrence and
metastasis was valuable and sensitivity was evaluated as 92%,
and specificity as 81% [49,50].
3. Therapy
The decision on the therapy of invasive breast cancer de-
pends on several factors such as the cancer stage, the tumor size
and type, pathological and cytological status of the tumor, the
patient's opinion, the presence or absence of estrogen and pro-
gesterone receptors in the cytoplasm of tumor cells and so on
[51,52].
3.1. Stage I: two general therapy methods
Two general therapy methods are: modified radical mastec-
tomy or modified radical mastectomy including total mastec-
tomy and axillary dissection; breast conservation therapy or
conservative therapy of breast including lumpectomy and axil-
lary dissection followed by radiotherapy for 5 d a week, for 6
weeks, which is delivered at 4500–5000 centigray [53].
The studies have shown that the percentage of tumor recur-
rence in both methods is approximately equal and using each of
these two methods is different depending on the surgeon and
patient. Some investigations evaluated the breast conservation
therapy method in terms of the quality of life and mental health
of women [54,55].
In both methods, the mammography of the treated patient
should be done every 6 months until the surgery becomes stable
and once a year after it [56].
3.2. Therapy of locally advanced disease without
metastasis (stages IIIA, IIIB)
These patients primarily need chemotherapy and after it
surgery, radiation, or both should be performed but the likeli-
hood of tumor recurrence is more than the previous group and is
about 30%–50%. The results have shown that the method of
excision and radiotherapy is more acceptable than total mas-
tectomy. High-risk patients in this group should be checked
every three months and all patients with local recurrence in this
group should be checked in terms of visceral and bone metas-
tases and should also be evaluated in terms of systemic
chemotherapy and hormone therapy [57,58].
3.3. Stage IV
This stage that has been expanded further from breast and
axillary lymph nodes is considered incurable and the life ex-
pectancy at this stage is estimated about 24 months but it has
been observed that some patients with bone involvement and its
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stay alive for years despite their advanced disease [59]. Therapy
at this stage is based on chemotherapy and hormone therapy and
the surgery can be done only when the patient's tumor shows
specific signs. Although some studies have recommended that
the surgery in primary tumors and metastatic sites can help
extend the life of these patients and enhance the survival rate
[60,61].3.4. Adjuvant therapy
The adjuvant therapy is used when there are no visible tu-
mors and occur to delay the metastasis and includes chemo-
therapy or hormone therapy [62,63]. The decision for hormone
therapy in patients with metastatic breast depends on the
presence or absence of estrogen and progesterone receptors in
the cytoplasm of tumor cells. Up to 60% of patients with
metastatic breast cancer will respond to hormone therapy if the
estrogen receptors are positive and up to 80% of patients with
progesterone receptors will respond to hormone therapy, but
probably they do not have anything to respond to
chemotherapy [64,65].
The previous studies have reported that the status of axillary
nodes and whether the patient is postmenopausal or not play a
role in the survival of the patient's life, so that the risk of mor-
tality from diseases with the involvement of one to three lymph
nodes is twice the patients who do not have any involvement
[66]. The recurrence rate in women below 50 years after five
years of taking tamoxifen is more than women over 50 years [67].
Today, in some cases of hyperthermia, raising the tempera-
ture of the tissue to about 40–43 C is recommended as an
adjuvant therapy [68].
In adjuvant therapy, tamoxifen which is an antiestrogen drug
is widely used. The effect of tamoxifen for breast cancer pre-
vention in high-risk people is being studied [69]. Although
tamoxifen has different effects on the body, the drug inhibits
the estrogen receptors in the body, prevents estrogen
conversion to estradiol sulfate and ultimately inhibits the
protein kinase. Thus, it causes a slight increase in the risk of
endometrial cancer and a series of biochemical changes
independent of estrogen receptors in the body, including the
effect on the endocrine glands, venous thrombosis and eye
problems that should be considered in the long-term consump-
tion of tamoxifen [70,71].
Using other drugs in combination with tamoxifen has had
better results although with more toxicity [72].
For example, the use of medroxyprogesterone acetate causes
a large weight gain. Other examples could be megestrol and
aromatase inhibitors [73,74]. Also, the results of both
cyclophosphamide and doxorubicin-based chemotherapy have
been reported better than other drugs such as epirubicin [75].
Other methods of adjuvant therapy can be oophorectomy and
radiating the ovary that has great influence in increasing the
survival rate [76,77].
The decision on the therapy of invasive breast cancer de-
pends on several factors such as the cancer stage, the tumor size
and type, pathological and cytological status of the tumor, the
patient's opinion, the presence or absence of estrogen and pro-
gesterone receptors in the cytoplasm of tumor cells and so on. In
total, there have been no proved findings about the use of
therapies for these patients and relieving the patient's pain andimproving his/her quality of life and above all the patient's
opinion on the therapy type must be highly considered.
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